On Tuesday, Harmony Biosciences Holdings Inc (NASDAQ: HRMY) opened lower -1.78% from the last session, before settling in for the closing price of $33.07. Price fluctuations for HRMY have ranged from $27.10 to $41.61 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 546.41%. Company’s average yearly earnings per share was noted 8.85% at the time writing. With a float of $40.49 million, this company’s outstanding shares have now reached $56.77 million.
Let’s determine the extent of company efficiency that accounts for 246 employees. In terms of profitability, gross margin is 76.9%, operating margin of 25.71%, and the pretax margin is 25.71%.
Harmony Biosciences Holdings Inc (HRMY) Insider Activity
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Harmony Biosciences Holdings Inc is 29.00%, while institutional ownership is 65.82%. The most recent insider transaction that took place on Nov 01 ’24, was worth 121,210,000. In this transaction 10% Owner of this company sold 4,000,000 shares at a rate of $30.30, taking the stock ownership to the 7,218,033 shares. Before that another transaction happened on Nov 05 ’24, when Company’s 10% Owner sold 600,000 for $30.30, making the entire transaction worth $18,181,500. This insider now owns 6,618,033 shares in total.
Harmony Biosciences Holdings Inc (HRMY) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 8.85% per share during the next fiscal year.
Harmony Biosciences Holdings Inc (NASDAQ: HRMY) Trading Performance Indicators
Check out the current performance indicators for Harmony Biosciences Holdings Inc (HRMY). In the past quarter, the stock posted a quick ratio of 3.20. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.72. Likewise, its price to free cash flow for the trailing twelve months is 8.41.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 2.11, a number that is poised to hit 0.68 in the next quarter and is forecasted to reach 3.18 in one year’s time.
Technical Analysis of Harmony Biosciences Holdings Inc (HRMY)
Looking closely at Harmony Biosciences Holdings Inc (NASDAQ: HRMY), its last 5-days average volume was 0.52 million, which is a jump from its year-to-date volume of 0.48 million. As of the previous 9 days, the stock’s Stochastic %D was 11.73%. Additionally, its Average True Range was 1.55.
During the past 100 days, Harmony Biosciences Holdings Inc’s (HRMY) raw stochastic average was set at 26.90%, which indicates a significant increase from 25.80% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 38.81% in the past 14 days, which was lower than the 56.53% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $35.80, while its 200-day Moving Average is $32.96. However, in the short run, Harmony Biosciences Holdings Inc’s stock first resistance to watch stands at $33.01. Second resistance stands at $33.55. The third major resistance level sits at $33.88. If the price goes on to break the first support level at $32.15, it is likely to go to the next support level at $31.82. Should the price break the second support level, the third support level stands at $31.28.
Harmony Biosciences Holdings Inc (NASDAQ: HRMY) Key Stats
There are currently 57,031K shares outstanding in the company with a market cap of 1.85 billion. Presently, the company’s annual sales total 582,020 K according to its annual income of 128,850 K. Last quarter, the company’s sales amounted to 186,040 K and its income totaled 46,090 K.
